Jonathan D. Cheng

发表论文 178 篇 · 总被引 27124 次 · h-index 52

代表论文

• Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study (2019 · The Lancet · 被引 3347)
• Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study (2020 · Clinical Cancer Research · 被引 113)
• Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma (2022 · Journal for ImmunoTherapy of Cancer · 被引 97)
• Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: KEYNOTE-412 (2020 · Future Oncology · 被引 58)
• Biomarkers predictive of response to pembrolizumab in head and neck cancer (2022 · Cancer Medicine · 被引 51)
• Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040 (2020 · JNCI Journal of the National Cancer Institute · 被引 39)